Background:
Cardiomyopathy is a global health crisis that affects people all over the
world. Consequently, scientists felt compelled to look for and develop ever-more-powerful
pharmaceuticals. For ATTR-CM, the only drug currently recommended by the European Society
of Cardiology is Tafamidis.
Objectives:
The primary aim of this review article is to understand the chemistry, pharmacodynamic,
pharmacokinetic, and bio-analytical methods available for Tafamidis
Methods:
A systematic review of the existing resources was accomplished up to 2022, comprising
existing studies forming the database covering the existing resources from Web of Science,
ScienceDirect, and PubMed.
Results:
The review was based on a systematic review of all the existing studies used to formulate
the database. The study also illustrated the PRISMA design that systematically analyses the
prevalent resources.
Conclusion:
Minimal analytical techniques are observed for quantifying the Tafamidis and
transthyretin kinetic stabiliser. Therapeutic, pharmacological, and analytical considerations for
the novel drug Tafamidis are discussed in this review. Particular attention is paid to the many
different analytical and bioanalytical methods currently available for estimating Tafamidis, and
the need is highlighted to develop a straightforward, validated technique that meets green chemistry
standards.